Targeted Strategies for Today's Evolving Markets

MissionIR Blog

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Built Strategically from Day One

  • The company delivers premium, certified organic cannabis to Canada and international markets
  • TGOD intends to explore strategic international markets with exclusive licensing deals and partnerships
  • The company has set its sights on the beverage industry as it continues to look forward

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a premium, global organic cannabis firm, is creating a sustainable and successful company through its careful planning and strategic growth strategy implementation. The company is focused on the medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market.

TGOD’s strategic approach is unique, combining a focus on growing organic products and implementing logistical and infrastructure controls not often seen with industry competitors. This results in a premium crop. The company has also partnered with the world’s second-largest power management company, Eaton, and Canada’s second-largest construction management company, Ledcor, to ensure ultimate use of space and power. One of only three certified organically grown cannabis companies in Canada, TGOD is committed to maintaining a competitive edge at home and abroad.

TGOD’s vision is to become the global leader in delivering premium organic cannabis solutions that enhance its customers’ lives. The company’s product and process of growth are certified organic by the industry’s leading certification bodies, Ecocert and ProCert. TGOD is producing high-quality cannabis in living soil with established organic growing techniques and leading-edge intellectual property. Its living soil is free of pesticides, herbicides and synthetic nutrients, and products grown in this medium command a premium price.

TGOD’s focus on quality control and production efficiency have enabled it to enjoy healthy profit margins, and the company is acting on its mission to become a household name in the global cannabis community. To become a global leader, TGOD consistently explores strategic international opportunities. The company has already secured exclusive licensing deals in Canada and select international markets. Through a partnership with Epican, a vertically integrated Jamaican cannabis company in which TGOD has acquired a 49.18 percent interest, TGOD provides a platform to export its branded, premium Jamaican-grown cannabis products to select international jurisdictions for medical purposes. A joint venture with Denmark’s Queen Genetics/Knud Jepsen aims to develop and patent innovative and commercially valuable, elite cannabis genetics. The combined run rate of the Canadian-located Hamilton and Valleyfield facilities, along with the Jamaican domestic expansion and Denmark pilot, ramp up TGOD’s production to 219,000 kg, and the company hasn’t stopped there.

HemPoland, a fully owned subsidiary of TGOD, is providing a strategic cannabis gateway to the 750 million people in Europe, while a joint venture with LLACA provides access to 7,600 potential retail locations in Mexico and its 640 million residents.

Every element of The Green Organic Dutchman – from the ground up – has been planned carefully, deliberately and strategically. TGOD is ideally located in Ontario and Quebec to reduce shipping distance and provide higher customer satisfaction with lower operating expenses in Canada. The two provinces represent almost two-thirds of the Canadian population, allowing TGOD to simplify logistics. The provinces also border six U.S. states, allowing the company to capitalize on an estimated 57 million potential recreational cannabis tourists. TGOD provides coast-to-coast distribution in Canada through Velvet Management Inc., a well-known distribution company, established in 1968, that manages the largest wine sales force in the country.

By leveraging innovative tech and low-cost power solutions, the company is positioned to be one of the highest-quality and lowest-cost producers in Canada. This is in large part due to strategic partnerships with Eaton, Ledcor Group and Hamilton Utilities Corp. These partnerships allow TGOD to build the most advanced hybrid facilities in Canada capable of producing cannabis at some of the lowest costs today.

Grown organically and at low costs, the final product demands a premium price in the marketplace, increasing TGOD’s margins.

As the company continues to look to the future, it has set its sights on the beverage industry. A 40,000-square-foot Innovation Campus is in the planning stages and will focus on developing consumer-preferred products across a wide range of categories and occasions. The company wants to explore high-quality organic edibles and beverages, a plan that provides TGOD with a strategic path into the large-scale beverage, beverage alcohol and cannabis edibles markets.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in The Green Organic Dutchman Holdings Ltd. TGODF | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Developing Novel Nicotine Ingestion Method as Smoking Alternative

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An article further discussing the company reads, “The technology, known as DehydraTECH(TM), is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe). . . . The deal funds Lexaria’s R&D program — and consumer product development — in exchange for certain DehydraTECH license rights and a minority equity interest in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An initial tranche of $1 million has been provided, with additional phases providing up to $12 million total. Lexaria has granted a license for its technology to be used in nicotine-based, oral-format products on an exclusive basis in the United States and a nonexclusive basis elsewhere globally, for which it will receive royalties on every dollar of revenue generated utilizing its technology.”

To view the full article, visit http://ibn.fm/dvdIc

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in more than 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR,” covers INmune’s INB03 Program that utilizes dominant negative TNFα (“DN-TNFα”) technology for treating cancer. “This is an important patent for INmune Bio, Inc. and provides exclusivity for use of our DN-TNFα technology for the treatment of cancer,” INmune Bio Assoc. General Counsel Joshua Schoonover said in the news release. “With the approval from the USPTO, and the positive indication of allowable subject matter in the international preliminary report on patentability for the corresponding international PCT patent application, published as WO/2017/106278, we expect this patent family should develop into global intellectual property rights.”

To view the full press release, visit http://ibn.fm/r6n5k

About INmune Bio, Inc.

INmune Bio, Inc. is a clinical-stage immunology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing two product platforms, the DN-TNFα Platform and an Immune Priming Platform, as well as multiple products related to these platforms that reengineer the patient’s innate immune system’s response to disease. In addition to INB03, the DN-TNFα Platform includes XPRO1595, a DN-TNFα protein biologic that targets soluble TNFα (sTNFα) and may have many beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation; and NeuLiv, also a DN-TNFα protein biologic that may enable targeting of the underlying cause of non-alcoholic steatohepatitis (NASH), to help stop the disease and allow the liver to heal. The Immune Priming Platform includes INKmune, which is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and neurodegenerative diseases. For more information, visit the company’s website at www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in INmune Bio Inc. INMB, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Accelerate Shipments to Meet Demand for Premium Organic Cannabis Following Ontario Launch

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, today announced that initial demand has exceeded expectations following its August launch in Ontario, which marked the company’s entrance into Canada’s recreational market. Per the update, TGOD’s Unite Organic, a high-THC signature strain, is performing well online and at dispensaries and triggering a second OCS order earlier than initially anticipated. “We are thrilled to witness such strong sales and positive feedback from retailers and consumers across Ontario, Canada’s most populous province at 14.32 million people.  We can see from the initial response that demand for high-quality flower is strong,” TGOD CEO Brian Athaide said in the news release. “Our team is working hard to ramp up production of our premium organic products as we get ready to expand distribution with additional strains and product forms as well as to other provinces in the months ahead.  With our Hamilton hybrid greenhouse completed, and a second one nearing completion in Valleyfield, we are on track to distribute nationally early next year.”

To view the full press release, visit http://ibn.fm/fPAGn

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly-owned subsidiary HemPoland distributes premium hemp CBD oil in EU. The company grows high-quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, The Green Organic Dutchman Holdings Ltd. TGODF | Leave a comment

BMO Completes Placement of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Block

  • BMO’s block offering of TGOD’s shares was fully subscribed
  • TGOD’s CEO commented on the mutual benefits presented by the Aurora transaction
  • Investment interest in TGOD has been heightened following completion of the transaction

In the wake of The Bank of Montreal’s (BMO) completion of a block trade of Aurora Cannabis (TSX: ACB) (NYSE: ACB) held shares of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), leadership is reportedly pleased to see that 28.8 million overhanging shares remaining from that transaction have been successfully placed, predominately with institutional asset managers.

Through a transaction with BMO, a block trade of 4.8 million shares was completed on Friday, September 6, at $2.96, clearing the remaining shares. Approximately 55-65 percent of the total block of shares was placed in the hands of institutional asset managers, with the balance being taken by retail investors. This transaction was felt by both parties to be beneficial to their long-term strategic goals. Due to the repatriation of TGOD’s premium organic cannabis, which was previously designated for Aurora, the transaction brings significant revenue and gross margin gains for TGOD. ACB continues to show its support for TGOD by maintaining over 16.6 million purchase warrants (http://ibn.fm/D5LKg).

“Aurora has been an excellent partner during TGOD’s build out phase; their investment was instrumental in our success,” Brian Athaide, CEO of TGOD, stated in a news release (http://ibn.fm/ewIIy). “The relationship added tremendous value across multiple areas of collaboration, including the initial design and construction of our Canadian facilities. This is the right next step in the relationship as both companies mature and our respective strategies evolve, also providing TGOD with new institutional investors.”

This clearing of the stock overhang enables TGOD to increase its number of institutional holders, and industry analysts have described TGOD’s stock as “a screaming deal” for interested investors.

TGOD is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in The Green Organic Dutchman Holdings Ltd. TGODF | Leave a comment

MissionIRNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”

To view the full press release, visit http://ibn.fm/0ZRIh

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Announces Formation of Strategic Advisory Board

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced the formation of its Strategic Advisory Board. According to the update, the group of respected business leaders, which includes inaugural board members John Ruffolo, Meg Lovell and Philip Donne, will provide guidance to Canopy Rivers’ executive team as it continues to build and strengthen its global portfolio of leading cannabis companies. “We have assembled a group of outstanding individuals with exceptional track records as leaders in their respective industries,” Canopy Rivers President and CEO Narbe Alexandrian said in the news release. “The Strategic Advisory Board will play an important role in providing guidance and insight to Canopy Rivers as we pursue our global growth strategy. Together, we look forward to building the cannabis industry of tomorrow, today.”

To view the full press release, visit http://ibn.fm/cBm34

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Canopy Rivers Inc. CNPOF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and Potential Use in Clinical Diagnostics

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the publication of two scientific journal articles led by independent teams of scientists in China and Australia. Per the update, the articles reported excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers, as well as potential use in clinical diagnostics based upon these markers. “It is estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year,” Pressure BioSciences President and CEO Richard T. Schumacher said in the news release. “These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.”

To view the full press release, visit http://ibn.fm/QhPt0

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

Earth Science Tech Inc.’s (ETST) CBD Oil is Unique in the Industry

  • Earth Science Tech is looking to expand its line of work through two wholly owned subsidiaries
  • Its subsidiaries focus on R&D and product development
  • The company recently outlined a five-year marketing and manufacturing plan

Earth Science Tech Inc. (OTCQB: ETST) is an aspiring biotech company engaged in the development of cannabinoid-based products and the research and development of medical devices and pharmaceuticals. Using the supercritical CO2 liquid extraction, isolation and micron filtration process, the company manufactures 100 percent natural CBD oil. This pure, easily digested, rich CBD hemp oil is unique to the nutraceuticals industry and represents a significant asset to ETST.

Earth Science Tech is currently looking to expand its operations in the areas of CBD product development and R&D of medical devices and pharmaceuticals through its two wholly owned subsidiaries: Earth Science Pharma Inc. and Cannabis Therapeutics Inc.

Earth Science Pharma Inc. is focused on the research and development of low-cost medical devices and vaccines that benefit women’s health. The company recently introduced its first medical device, MSN-2, a home kit designed for the detection of STIs such as chlamydia. The company has named this kit Hygee. By circumventing the need for laboratory analysis, ETST anticipates that the kit will empower women across the world, giving them a low-cost, noninvasive method to meet their diagnostic health care needs (http://ibn.fm/HROu1).

Aside from Earth Science Pharma’s innovations in the diagnostic health care space, ETST has another subsidiary operating in the burgeoning cannabis industry. Cannabis Therapeutics Inc. is committed to the research and development of medicinal cannabidiol. The company also possesses a provisional application patent for a CBD product that can be used for developing medications to treat breast and ovarian cancers.

ETST recently filed a 10-K annual report with the SEC that included an outline of the company’s five-year expansion plan for manufacturing and marketing its CBD products (http://ibn.fm/JY9mT). The plan includes information about the company’s strategic preparations to scale up the production of its CBD oil, introduce new products and make its innovative hemp products available worldwide (http://ibn.fm/5OZ0R).

Earth Science Tech has teamed up with the University of Central Oklahoma to conduct research and development projects. In addition, studies from the DV Biologics Laboratory scientifically support and advance the health care benefits of the company’s high-grade hemp CBD oil. These studies show positive results regarding breast cancer and immune cells to support that ETST’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive-result case studies conducted through key health organizations.

“Our CBD-rich hemp oil does not contain any synthetic cannabinoids and is not an isolate,” the SEC report noted. “It contains everything that is naturally occurring in the original industrial hemp plant. With our high-quality, CBD-rich hemp oil you benefit from the natural interaction of phytonutrients in their balanced wide-ranging form that may offer the most benefit for overall wellness.” The report further noted that the company’s “commercialized, CBD-based product line, High-Grade Full Spectrum Cannabinoids, offers seven distinct cannabinoids maximizing all the therapeutic benefits the industrial hemp plant has to offer.”

Through the innovative products offered by its two wholly owned subsidiaries, ETST is well-positioned to stay abreast of current trends in multiple markets.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Earth Science Tech, Inc. ETST | Leave a comment

MissionIRNewsBreaks – Canopy Rivers Inc.’s (TSX: RIV) (OTC: CNPOF) Herbert Works Awarded Health Canada R&D License to Develop Cannabis-Infused Beverages

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced that its portfolio company Herbert Works Ltd. has received its Health Canada research and development (R&D) license to develop branded cannabis-infused beverages. “This announcement represents a significant milestone for Herbert Works as the company continues to move quickly toward the development of exceptional and widely appealing THC-infused beverages,” Canopy Rivers President and CEO Narbe Alexandrian said in the news release. “It’s a timely achievement, as the next wave of cannabis legalization in Canada will unlock these new product offerings in a matter of months. We believe that Herbert Works is in a prime position to capitalize on the growth opportunities that ‘Cannabis 2.0′ presents for consumers that are eager to try cannabis in different formats.”

To view the full press release, visit http://ibn.fm/8tQBw

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Canopy Rivers Inc. CNPOF, MissionIRNewsBreaks | Leave a comment